Veridex Launches CELLTRACKS® Circulating Melanoma Cell Kit for Re... ( RARITAN N.J. May 24 2011 /- Veridex L...)

Veridex Launches CELLTRACKS® Circulating Melanoma Cell Kit for Research Use

Date:5/24/2011

RARITAN, N.J., May 24, 2011 /PRNewswire/ -- Veridex, LLC today announced the launch of the CELLTRACKS® Circulating Melanoma Cell (CMC) kit, providing research scientists with a fast, convenient and reliable way to capture CMCs for research studies. Using proprietary immunomagnetic technology to capture and count CMCs, the CELLTRACKS® CMC kit is designed to offer data that support researchers engineering investigational therapies that are based on a specific protein or mutation.

"The CELLTRACKS® CMC kit is an essential research tool to enable melanoma cell capture for the oncology community," said Mark Connelly, Ph.D., Director of Cellular Research & Development for Veridex and co-author of the study Circulating Melanoma Cells and Survival in Metastatic Melanoma published in the January 2011 edition of the International Journal of Oncology. "Current methods of melanoma cell capture, such as biopsy and polymerase chain reaction (PCR), are time intensive. This new kit will automate the process, making it simple and reproducible."

The CELLTRACKS® CMC kit is an innovative enabling technology for using biomarkers to identify and enumerate CMCs, melanoma cells that have detached from tumors and entered the blood stream. Based on the same immunomagnetic technology that powers Veridex's CELLSEARCH® technology, researchers can use the kit to capture CMCs and then select a protein biomarker of their choosing to further refine their research. The technology used in the CELLSEARCH® System to capture and count circulating tumor cells (CTCs) was ranked as the top medical innovation for 2009 by the Cleveland Clinic, a leading multispecialty academic medical center and honored with the prestigious Prix Galien USA Award for "Best Medical Technology."

About Circulating Melanoma Cells

The CMC kit is intended for research use only. Performance characteristics have not been established. In 2010, 84 mela
'/>"/>

SOURCE Veridex, LLC
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Veridex, LLC Announces Collaboration to Develop Next-Generation Circulating Tumor Cell (CTC) Technology with Massachusetts General Hospital
2. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
3. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
4. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
5. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
6. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
7. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
8. Premier Micronutrient Launches Supplement for Hearing Health
9. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
10. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
11. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control

Post Your Comments:

(Date:6/19/2013)... EMERYVILLE, Calif. , June 19, 2013 /PRNewswire/ ... performance management solutions, introduced the next-generation of its ... solution, which allows health plans to provide their ... their populations, health factors, medical and prescription drug ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) ...

(Date:6/19/2013)... , 19. Juni 2013 /PRNewswire/ ... dass mit der Entwicklung von SCS ... Schritt in der Beschichtung mit Parylene ... Vorteile von biokompatiblem Parylene mit antimikrobiellen ... Beseitigung schädlicher Mikroorganismen auf beschichteten medizinischen ...

(Date:6/18/2013)... MILAN , June 19, 2013 ... in fluctuating Parkinson,s disease (PD) patients as add-on ... clinically important improvement in motor symptoms in fluctuating ... Newron Pharmaceuticals S.p.A. ("Newron"), a ... and pain therapies, and its partner Zambon S.p.A., ...

Breaking Medicine Technology:MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2 Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2 Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2 Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3 Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4 Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5 Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6

[0] MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution [0] Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt [0] Safinamide Phase III Study Results Presented at 2013 MDS Meeting

... At its annual R&D,event being held today in ... will,provide an update on progress in all aspects ... rollout for its growing range of,DNA-based diagnostic tests; ... progress in its drug development,programs; and how the ...

... June 30 deCODE genetics,(Nasdaq: DCGN ... its latest,clinical pharmacology study of DG041, the ... prostaglandin E2, developed as a,next-generation oral anti-platelet ... risk. The prospective, randomized,blinded, crossover study compared ...

Cached Medicine Technology:Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event 2 Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event 3 DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin 2 DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin 3 DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin 4

Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin

(Date:6/19/2013)... Center and colleagues at Louisiana State University have developed ... immediate therapy. It relies on understanding the genetic interaction ... better predict a prostate cancer,s aggressiveness to avoid unnecessary ... the online journal PLOS ONE in April. ... 20 percent of all cancers and 9 percent of ...

(Date:6/19/2013)... DiscountFurnaceFilter.com, the number one solution for homeowner’s indoor ... Saver kit at an exceptional price. The 5-2-1 Compressor Saver ... conditioning unit during start up, saving wear and tear on ... burn out. , The 5-2-1 Compressor Saver works ... less power to start and drastically reduces the rush of ...

(Date:6/19/2013)... June 19, 2013 Alternatives, a revolutionary ... patients to quit using drugs while allowing them to ... the founders of Alternatives, believe that abstinence-only approaches force ... enter treatment and that this approach hurts instead of ... in the United States need treatment for addiction but ...

(Date:6/19/2013)... City, MO (PRWEB) June 19, 2013 Kansas City ... part of Main Street Day . A section of Main ... pedestrian traffic during the afternoon of the event. The Main ... host the event, which will help Kansas City join the ranks ... used Ciclovia as a tool to foster community vibrancy and active ...

(Date:6/19/2013)... Washington (PRWEB) June 19, 2013 ... physicians deem it medically necessary, according to a ... and Child Health Journal. The results of this ... for more than a decade – that trying-to-conceive ... and maintaining a healthy body weight. Fairhaven Health ...

Breaking Medicine News(10 mins):Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2 Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2 Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3 Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2 Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3 Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2 Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3 Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4

[0] Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers [0] DiscountFurnaceFilter.Com is Pleased to Offer the 5-2-1 Compressor Saver Kit at an Exceptional Price [0] Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment [0] Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia [0] Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies

... , MISSISSAUGA, Ontario, July 31 ... that it has completed the acquisition of CardioGenics Inc. by ... with the acquisition, ExchangeCo acquired all of the outstanding shares ... in the aggregate owned by two (2) minority stockholders of ...

... AURORA, Ohio, July 31 Arizona Cardinals 2008 NFC West Champions, wide-receiver, ... vision problems can interfere with a child,s ability to pay attention, read ... vision or 20/20 vision , your child could still ... warns Fitzgerald. , , Do you have a ...

... NEW YORK, July 31 Duane Reade Holdings, Inc. announced ... Reade (collectively, the "Issuers"), had priced their offering of $300,000,000 ... 2015 (the "Notes"). The Notes will bear interest at ... at 97.417%, representing a yield to maturity of 12.375%. ...

... , PLEASANTON, Calif., FRAMINGHAM, ... THOR ), a world leader in device-based ... failing hearts, and HeartWare International, Inc. (Nasdaq: HTWR/ASX: HIN), ... today they have mutually agreed to terminate their merger ...

... 31 In a post-recession America, even though as a nation income ... crushing burden of health care costs and will watch their standards of ... the New England Journal of Medicine (NEJM) by Daniel ... University of Pennsylvania,s Leonard Davis Institute of Health Economics. , ...

... , , , ... and the expression of dance and movement have an incredible ability ... art therapy, dance and movement therapy and equine therapy, have the ... including substance abuse, eating disorders, abuse issues, depression, anxiety, relationship problems ...

Cached Medicine News:Health News:JAG Media Holdings, Inc. Announces Completion of Acquisition of CardioGenics Inc. 2 Health News:JAG Media Holdings, Inc. Announces Completion of Acquisition of CardioGenics Inc. 3 Health News:JAG Media Holdings, Inc. Announces Completion of Acquisition of CardioGenics Inc. 4 Health News:NFL Cardinals' Wide Receiver Larry Fitzgerald Promotes Vision Therapy 2 Health News:NFL Cardinals' Wide Receiver Larry Fitzgerald Promotes Vision Therapy 3 Health News:NFL Cardinals' Wide Receiver Larry Fitzgerald Promotes Vision Therapy 4 Health News:Duane Reade Holdings, Inc. Announces Pricing of Offering of 11.75% Senior Secured Notes Due 2015 2 Health News:Duane Reade Holdings, Inc. Announces Pricing of Offering of 11.75% Senior Secured Notes Due 2015 3 Health News:Thoratec Corporation and HeartWare International, Inc. Announce Termination of Proposed Transaction 2 Health News:Thoratec Corporation and HeartWare International, Inc. Announce Termination of Proposed Transaction 3 Health News:Post-Recession Incomes Will Be Hit Hard by Health Care Spending for Middle Class Working Families, PENN Analysis Shows 2 Health News:Post-Recession Incomes Will Be Hit Hard by Health Care Spending for Middle Class Working Families, PENN Analysis Shows 3 Health News:Post-Recession Incomes Will Be Hit Hard by Health Care Spending for Middle Class Working Families, PENN Analysis Shows 4 Health News:The Healing Power of Art, Dance and Expression 2 Health News:The Healing Power of Art, Dance and Expression 3

JAG Media Holdings, Inc. Announces Completion of Acquisition of CardioGenics Inc.NFL Cardinals' Wide Receiver Larry Fitzgerald Promotes Vision Therapy Duane Reade Holdings, Inc. Announces Pricing of Offering of 11.75% Senior Secured Notes Due 2015 Thoratec Corporation and HeartWare International, Inc. Announce Termination of Proposed Transaction Post-Recession Incomes Will Be Hit Hard by Health Care Spending for Middle Class Working Families, PENN Analysis Shows The Healing Power of Art, Dance and Expression

Worn by many professional athletes, EpiTrain is our most popular elbow support....

... combines the therapeutic benefits of controlled compression ... to minimize pain. The cuff is anatomically ... maximum cryotherapy. The Elbow Cryo/Cuff is available ... a pediatric size.,All Cryo/Cuffs can be ordered ...

... The Cryo/Cuff for Walking Brace is designed ... to the Aircast PneumaticWalker™ (sold separately). When ... cold water, the cuff surrounds the foot ... to minimize hemarthrosis, swelling, and pain.,All Cryo/Cuffs ...

... support helps reduce swelling and minimize pain while ... easy to apply - it slips on like ... into shoes. It features bilateral spiral stays ... support and stability. This is an excellent ...

Medicine Products:

EpiTrain Elbow Cryo/Cuff™Cryo/Cuff™ for Walking Brace 2560 ANKLE SUPPORT WITH SPIRAL STAYS